[The relation between the level of antibodies to the glycosaminoglycans of the cartilage in patients with osteoarthritis and the efficacy of treatment with chondroprotectors].

Aim: To improve the efficacy of osteoarthrosis (AO) treatment by chondroprotectors by defining individual indications for their use, based on the initial level of antibodies to cartilaginous glycosaminoglycans (GAG) in the blood serum.

Materials And Methods: Anti-GAG were detected by indirect solid-phase enzyme immunoassay. The antigen was a sulfated GAG preparation GAG-polysulfate (arteparon) manufactured by Luitpold-Werk (Germany).